Subtype
Nasopharyngeal Carcinoma
CI-CAN-00008100NPCExplore in graph →
246 active trials1 approved drugs
- NCIt
- C3871
- OncoTree
- NPC
- UMLS CUI
- C2931822
- MeSH
- D000077274
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00008100NPCExplore in graph →
Clinical trials
702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | recruiting | Phase 1 / Phase 2 | 202 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 |
| clinicaltrials |
| NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07154069 | Adaptive Immunotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 802 | Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248670 | Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC | active not recruiting | Phase 3 | 252 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248696 | Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial | active not recruiting | N/A | 32 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06839066 | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | recruiting | Phase 2 | 70 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232680 | Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy(IMPRINT) | recruiting | — | 500 | Cheng-En HsiehOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07238569 | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 516 | Sun Yat-sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT07088861 | Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China | active not recruiting | — | 1,401 | Lirong WuOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT06982300 | SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC(NACASOR) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07198802 | Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma | not yet recruiting | — | 600 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06509009 | Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | recruiting | Phase 2 | 208 | Ming-Yuan ChenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06241612 | Individualized Elective Neck Irradiation in NPC Patients | recruiting | Phase 3 | 470 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04384627 | Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy(NPC-GTV) | active not recruiting | Phase 3 | 445 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 30 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | terminated | Phase 3 | 10 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01744587 | Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients(NPC) | completed | N/A | 353 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05884983 | Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma | recruiting | — | 12,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02795195 | Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 51 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07088484 | Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | — | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 28, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07072000 | Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity | not yet recruiting | Phase 3 | 550 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03984357 | Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma(PLATINUM) | completed | Phase 2 | 152 | Sun Yat-sen UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04907370 | PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma(DIAMOND) | active not recruiting | Phase 3 | 532 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04833257 | Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC | completed | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06228079 | Adjuvant vs Surgery Only in Early-stage Recurrent NPC | recruiting | Phase 3 | 176 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07042711 | Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients | active not recruiting | N/A | 300 | Indonesia UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07019870 | Screening for Early Diagnosis of Nose Cancer | recruiting | N/A | 20,000 | National University Hospital, SingaporeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07011329 | Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.(NPC) | active not recruiting | — | 60 | Hubei Cancer HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04823468 | Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma | completed | N/A | 236 | Jinsheng HongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Dec 5, 2025source: clinicaltrials